Apoptosis in leukemia: From molecular pathways to targeted therapies

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 1, 2008, Pages 5-11

  Schimmer, Aaron D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

apoptosis; BCL2; caspase; inhibitors; targeted therapies; X linked inhibitors of apoptosis protein; XIAP

Indexed keywords

ABT 263; AEG 35156; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCL2 RELATED PROTEIN A1; BCL2 RELATED PROTEIN A1 INHIBITOR; CYCLOPHOSPHAMIDE; FLUDARABINE; MESSENGER RNA; OBATOCLAX; OBLIMERSEN; PROTEIN BCL XL INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EUPHORIA; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; MOLECULAR MECHANICS; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SOMNOLENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; HUMANS; LEUKEMIA; PROTO-ONCOGENE PROTEINS C-BCL-2; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 40749106485     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.11.002     Document Type: Review

References (27)

1. Schimmer A.D., Hedley D.W., Penn L.Z., et al. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 98 (2001) 3541-3553
2. Schimmer A.D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Research 64 (2004) 7183-7190
3. Schimmer A.D., Munk-Pedersen I., Minden M.D., et al. BCL2 and apoptosis in chronic lymphocytic leukemia. Current Treatment Options in Oncology 4 (2003) 211-218
4. Schimmer A.D., Dalili S., Batey R.A., et al. Targeting XIAP for the treatment of malignancy. Cell Death Differ 13 (2006) 179-188
5. Reed J.C. Proapoptotic multidomain BCL2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 13 (2006) 1378-1386
6. Konopleva M., Tari A.M., Estrov Z., et al. Liposomal BCL2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 95 (2000) 3929-3938
7. Hu Y., Bebb G., Tan S., et al. Antitumor efficacy of oblimersen BCL2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clinical Cancer Research 10 (2004) 7662-7670
8. O'Brien S., Moore J.O., Boyd T.E., et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (BCL2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 25 (2007) 1114-1120
9. Trudel S., Li Z.H., Rauw J., et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109 (2007) 5430-5438
10. Shore G.C., and Viallet J. Modulating the BCL2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology. American Society of Hematology. Education Program (2005) 226-230
11. Perez-Galan P., Roue G., Villamor N., et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109 (2007) 4441-4449
12. Borthakur G., O'Brien S., Ravandi-Kashani F., et al. A phase I trial of the small molecule pan-BCL2 family inhibitor obatoclax mesylate (GX15-070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia (CLL). Blood 108 (2006) 751a (abstr 2654)
13. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of BCL2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
14. Wilkinson J.C., Cepero E., Boise L.H., et al. Upstream regulatory role for XIAP in receptor-mediated apoptosis. Molecluar and Cellular Biology 24 (2004) 7003-7014
15. Berezovskaya O., Schimmer A.D., Glinskii A.B., et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Research 65 (2005) 2378-2386
16. Tong Q.S., Zheng L.D., Wang L., et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Therapy 12 (2005) 509-514
17. Tamm I., Richter S., Scholz F., et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. The Hematology Journal 5 (2004) 489-495
18. Tamm I., Richter S., Oltersdorf D., et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clinical Cancer Research 10 (2004) 3737-3744
19. Ranson M., Dive C., Ward T., et al. A phase I trial of AEG35156 (XIAP antisense) administered as a 7-day continuous intravenous infusion in patients with advanced tumors. Molecular Targets and Cancer Therapeutics (2005) 215 (abstr C72)
20. Sun H., Nikolovska-Coleska Z., Yang C.Y., et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. Journal of Medicinal Chemistry 47 (2004) 4147-4150
21. Sun H., Nikolovska-Coleska Z., Yang C.Y., et al. Structure-based design of potent, conformationally constrained Smac mimetics. Journal of the American Chemical Society 126 (2004) 16686-16687
22. Nikolovska-Coleska Z., Xu L., Hu Z., et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. Journal of Medicinal Chemistry 47 (2004) 2430-2440
23. Li L., Thomas R.M., Suzuki H., et al. A small molecule Smac mimic potentiates T. Science 305 (2004) 1471-1474
24. Wu T.Y., Wagner K.W., Bursulaya B., et al. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chemistry & Biology 10 (2003) 759-767
25. Schimmer A.D., Welsh K., Pinilla C., et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5 (2004) 25-35
26. Wang Z., Cuddy M., Samuel T., et al. Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. The Journal of Biological Chemistry 279 (2004) 48168-48176
27. Carter B.Z., Gronda M., Wang Z., et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 105 (2005) 4043-4050